N6037
奈立膦酸盐
≥97% (NMR), solid, bone resorption inhibitor
别名:
6-氨基-1-羟基亚己基双膦酸, 奈立膦酸, 奈立膦酸钠
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C6H17NO7P2
化学文摘社编号:
分子量:
277.15
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77
产品名称
奈立膦酸盐, ≥97% (NMR), solid
描述
may contain <1% (w/w) inorganic salts
质量水平
方案
≥97% (NMR)
表单
solid
颜色
white
溶解性
H2O: >5 mg/mL
储存温度
2-8°C
SMILES字符串
NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
InChI
1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
InChI key
PUUSSSIBPPTKTP-UHFFFAOYSA-N
相关类别
生化/生理作用
奈立膦酸是一种骨吸收抑制剂。它用于治疗成骨不全症。
奈立膦酸是一种骨吸收抑制剂。它用于治疗成骨不全症，一种“孤儿病”，其特征是骨骼极其脆弱以致于被成为“晶体骨骼疾病”。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Imène Chebbi et al.
International journal of pharmaceutics, 383(1-2), 116-122 (2009-09-15)
Bisphosphonates have been used for decades in the standard therapy of bone-related diseases, including bone metastasis of various malignancies, and they might as well be toxic on early cancer cells themselves. In order to allow a better delivery of neridronate
Luigi Gennari et al.
Mini reviews in medicinal chemistry, 9(9), 1052-1063 (2009-08-20)
Paget's disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, deformity and other complications leading to significant disability and bone pain. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 22(10), 1510-1517 (2007-07-04)
This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in
Role of neridronate on MCF-7 estrogen dependent breast cancer model of bone metastasis: a preliminary study.
Vanessa Nicolin et al.
Investigational new drugs, 29(1), 189-191 (2009-10-03)
Ombretta Viapiana et al.
Rheumatology (Oxford, England), 53(1), 90-94 (2013-09-27)
The objective of this study was to evaluate if the anti-inflammatory properties of bisphosphonates and their effect on bone turnover could be useful in the treatment of AS. Sixty patients were consecutively assigned in a 1:1 ratio in a 6-month
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持